Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by steve29caon Nov 29, 2011 8:59am

139 Views

Post# 19273732

RE: RE: RE: RE: RE: RE: RE: This stock sucks

Terry 1/2 the buyers of these small startup mines expect them to run like a gold mine thats been in production for a decade. They always forget that the SP they paid reflects the risks of startup. Those who have the time to make post after post about how crappy Brigus is I would suggest you sell your shares and buy something that you think is better. You can revisit Brigus in 2 years once the growing pains have been worked out and our mine is running smoothly and efficiently. Expect to pay more, the SP won't be a $1.30-$1.70 anymore.

Bullboard Posts

Debt-free cannabis company set for next stage of growth